PDE5 inhibitor ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
86	Pulmonary arterial hypertension	2

86. Pulmonary arterial hypertension

---

Clinical trials : 1,205 /  Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05039086 (ClinicalTrials.gov)	September 1, 2021	1/9/2021	Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5 Inhibitors vs Endothelin Receptor Antagonist	Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- PDE5 Inhibitors vs Endothelin Receptor Antagonist	Pulmonary Arterial Hypertension	Drug: PDE5 inhibitor;Drug: Endothelin Receptor Antagonists	Brigham and Women's Hospital	National Institute on Aging (NIA);Rutgers University;Johns Hopkins University	Active, not recruiting	65 Years	N/A	All	12947		United States
2	NCT01266265 (ClinicalTrials.gov)	December 2010	22/12/2010	Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies	A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution	Pulmonary Arterial Hypertension	Drug: inhaled prostacyclin;Drug: prostacyclin;Drug: subcutaneous and intravenous prostacyclin;Drug: oral ERA;Drug: oral PDE5 inhibitors	United Therapeutics	NULL	Completed	N/A	N/A	All	1333	N/A	United States